Pfizer (NYSE: PFE ) is certainly not letting AstraZeneca (NYSE: AZN )
slip away without a good fight. While Pfizer has been on a charm
offense on both sides of the ocean trying to convince politicians that
the deal is a legitimate business combination and not a cost-cutting tax
dodge, the company has also stepped up its financial consideration to
AstraZeneca shareholders. With AstraZeneca's board rejecting the latest
and according to Pfizer the "final" offer, it remains to be seen if the
international charm offensive can win over enough AstraZeneca
shareholders to lead them to put pressure on their board to come to the
negotiating table.
Read the full article here:
4th Time Not (Yet) the Charm for Pfizer
No comments:
Post a Comment